Antibody Information

General Information of This Antibody
Antibody ID
ANI0YYKFF
Antibody Name
AAJ8D6
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG
Antigen Name
Hepatocyte growth factor receptor (MET)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
AAJ8D6-Mc-Val-Cit-MMAE [Investigative]
 ADC Info 
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 85.49% (Day 21) Positive MET expression (MET+++/++)
Method Description
Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (1.1 mg/kg) via the tail vein on Day 0.
In Vivo Model Gastric cancer PDX model (PDX: LU2535)
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 21) Positive MET expression (MET+++/++)
Method Description
Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.
In Vivo Model Gastric cancer PDX model (PDX: GA0045)
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 21) Positive MET expression (MET+++/++)
Method Description
Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3.3 mg/kg) via the tail vein on Day 0.
In Vivo Model Gastric cancer PDX model (PDX: LU2535)
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 21) Positive MET expression (MET+++/++)
Method Description
Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.
In Vivo Model Gastric cancer PDX model (PDX: LU2535)
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 22.00% (Day 21) Positive MET expression (MET+++/++)
Method Description
Inoculate mice with MKN-45 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (0.75 mg/kg) via the tail vein on Day 0.
In Vivo Model MKN-45 CDX model
In Vitro Model Gastric adenocarcinoma MKN45 cells CVCL_0434
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 70.00% (Day 21) Positive MET expression (MET+++/++)
Method Description
Inoculate mice with MKN-45 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (1.5 mg/kg) via the tail vein on Day 0.
In Vivo Model MKN-45 CDX model
In Vitro Model Gastric adenocarcinoma MKN45 cells CVCL_0434
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.00% (Day 21) Positive MET expression (MET+++/++)
Method Description
Inoculate mice with MKN-45 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.
In Vivo Model MKN-45 CDX model
In Vitro Model Gastric adenocarcinoma MKN45 cells CVCL_0434
References
Ref 1 Anti-c-met antibody-drug conjugate and applications thereof; 2022-03-10.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.